Phase Ib Trial of M3814 with Lutetium Lu 177 Dotatate for Pancreatic Neuroendocrine Tumors
A phase Ib trial is investigating the combination of peposertib and lutetium Lu 177 dotatate for treating pancreatic neuroendocrine tumors.
Phase III
National Cancer Institute
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The ongoing phase Ib trial of M3814 in combination with lutetium Lu 177 dotatate represents a significant opportunity to enhance treatment options for pancreatic neuroendocrine tumors. Positive outcomes could lead to a new competitive therapy, impacting market positioning in oncology.
Recommended action
Humanexa recommends Monitor.
Analysis
Key milestones include dosing results and initial efficacy data from the trial.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.